Background: Compared with 10 years ago when our last survey was completed, the number of respiratory therapists (RTs) has increased markedly in mainland China. In addition, the education systems for RTs and the working environment have also changed. We aimed to describe the current status of respiratory care in mainland China.
Methods: A nationwide survey was initiated from August 15, 2016, to September 2, 2016, through network platforms.
Results: We obtained responses from 196 RTs, of whom, 30.6% graduated from a bachelor's degree program, 25.5% graduated from an associate's degree program, and 43.9% were nurses who transitioned to be RTs through 6-month on-the-job training programs. Among the 3 groups, no significant differences existed in the basic job responsibility, such as mechanical ventilation and aerosol therapy; however, bachelor's degree RT graduates participated more in bronchoscopy assistance (96% vs 78%, = .002), extracorporeal membrane oxygenation management (42% vs 25%, = .02), and pulmonary ultrasound (40% vs 15%, < .001). There was no RT certification or licensure in mainland China at the time of the survey, so only 23% of bachelor's degree graduates and 42% of associate's degree graduates received a license through other professions. For the respondents' opinions on the obstacles of respiratory care profession development, the lack of licensure was a profound barrier for both degree graduates, whereas on-the-job training RTs deemed that insufficient recognition of the value of the respiratory care profession was the main obstacle.
Conclusions: In mainland China, degree programs for students and on-the-job training for Experienced ICU nurses were 2 major ways to train RTs. The absence of credential and/or licensure and the lack of recognition of the value of an RT were deemed as the 2 key obstacles in the development of respiratory care profession.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4187/respcare.06217 | DOI Listing |
Pulmonology
December 2025
Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.
Pulmonology
December 2025
Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France.
Background: Nasal high flow (NHF) has been proposed to sustain high intensity exercise in people with COPD, but we have a poor understanding of its physiological effects in this clinical setting.
Research Question: What is the effect of NHF during exercise on dynamic respiratory muscle function and activation, cardiorespiratory parameters, endurance capacity, dyspnoea and leg fatigue as compared to control intervention.
Study Design And Methods: Randomized single-blind crossover trial including COPD patients.
Pulmonology
December 2025
Department of Emergency and Intensive Care, Fondazione IRCCS San Gerardo dei tintori, Monza, Italy.
Background: Non-invasive helmet respiratory support is suitable for several clinical conditions. Continuous-flow helmet CPAP systems equipped with HEPA filters have become popular during the recent Coronavirus pandemic. However, HEPA filters generate an overpressure above the set PEEP.
View Article and Find Full Text PDFPulmonology
December 2025
Alma Mater Studiorum, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Nasal high flow (NHF) therapy is an established form of non invasive respiratory support used in acute and chronic care. Recently, a new high flow nasal cannula with asymmetric prongs was approved for clinical use. The clinical benefits of the new cannula have not yet been defined and no evidence are available on the use of asymmetric NHF support in patient with Chronic Obstructive Pulmonary Disease (COPD).
View Article and Find Full Text PDFAdv Biotechnol (Singap)
January 2024
Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200030, China.
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) Variants of Concern (VOCs), such as the Omicron sub-variants, present significant challenges in pandemic control due to their capacity to escape antibodies and breach vaccine protections. Discovering antibodies that can tolerate mutations in VOCs and understanding their underlying mechanisms is crucial for developing therapeutics for COVID-19 patients, particularly those for whom other therapies may be unsuitable. Here, we report the neutralization of the Omicron variant by FD20, a broadly active human monoclonal antibody.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!